References

S
Spaulding AS, Kim AY, Harzke AJo, et al. Impact of new therapeutics for hepatitis C virus infection in incarcerated populations. Sullivan JC, Linas BP, Brewer A, et al., eds. Top Antivir Med. 2013;21(1):27-35.
Spaulding AC, Thomas DL. Screening for HCV infection in jails. JAMA. 2012;307(12):1259-1260.
Spaulding AC, Sharma A, Messina LC, et al. A comparison of liver disease mortality with HIV and overdose mortality among Georgia prisoners and releasees: a 2-decade cohort study of prisoners incarcerated in 1991. Zlotorzynska M, Miller L, Binswanger IA, eds. Am J Public Health. 2015;105(5):e51-e57.
Spaulding AC, Weinbaum CM, Lau DT, et al. A framework for management of hepatitis C in prisons. Sterling RK, Seeff LB, Margolis HS, Hoofnagle JH, eds. Ann Intern Med. 2006;144(10):762-769.
Spaulding AC, Seals RM, McCallum VA, Perez SD, Brzozowski AK, Steenland NK. Prisoner survival inside and outside of the institution: implications for health-care planning. Am J Epidemiol. 2011;173(5):479-487.
Stein MR, Soloway IJ, Jefferson KS, Roose RJ, Arnsten JH, Litwin AH. Concurrent group treatment for hepatitis C: implementation and outcomes in a methadone maintenance treatment program. J Subst Abuse Treat. 2012;43(4):424-432.
Stein BD, Gordon AJ, Dick AW, et al. Supply of buprenorphine waivered physicians: the influence of state policies. J Subst Abuse Treat. 2015;48(1):104-111.
Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatol. 2006;43(6):1317-1325.
Sterling RK, Zeuzem S, Wetzel T, et al. Safety and efficacy of glecaprevir/pibrentasvir for the treatment of HCV genotype 1-6: results from the HCV-TARGET study. International Liver Congress. 2019.
Strathdee SA, Latka M, Campbell J, et al. Factors associated with interest in initiating treatment for hepatitis C virus (HCV) infection among young HCV-infected injection drug users. O'Driscoll PT, Golub ET, Kapadia F, et al., eds. Clin Infect Dis. 2005;40(Suppl 5):S304-S312.
Su F, Green PK, Ioannou GN. The Association association between race/ethnicity and the effectiveness of direct antiviral agents for hepatitis C virus infection. Hepatology. 2017;65(2):426-438.
Su F, Green PK, Berry K, Ioannou GN. The association between race/ethnicity and the effectiveness of direct antiviral agents for hepatitis C virus infection. Hepatology. 2016;65(2):426-438.
Sulkowski MS, Eron JJ, Wyles DL, et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA. 2015;313(12):1223-1231.
Sulkowski MS, Chuang WL, Kao JH, et al. No evidence of reactivation of hepatitis B virus among patients treated with ledipasvir-sofosbuvir for hepatitis C virus infection. Clin Infect Dis. 2016;63(9):1202-1204.
Sulkowski MS, Sherman KE, Dieterich D, et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med. 2013;159(2):86-96.
Sulkowski MS, Hézode C, Gerstoft J, et al. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with HCV GT1 mono-infection and HIV/HCV coinfection (C-WORTHY): a randomised, open-label phase 2 trial. Vierling JM, Mallolas J, Pol S, et al., eds. Lancet. 2015;285(9973):1087-1097. doi:10.1016/S0140-6736(14)61793-1.
Sulkowski MS, Naggie S, Lalezari J, et al. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. Fessel WJ, Mounzer K, Shuhart M, et al., eds. JAMA. 2014;312(4):353-361.
Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. Reddy KR, Hassanein T, Jacobson IM, et al., eds. N Engl J Med. 2014;370(3):211-221.
Summa V, Ludmerer SW, McCauley JA, et al. MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrob Agents Chemother. 2012;56(8):4161-4167.
Suryaprasad AG, White JZ, Xu F. Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006–2012. Clin Infect Dis. 2014;(59):1411-1419.
Top